2017-03-10Mechanical coupling of cancer-associated fibroblasts and cancer cells through a heterotypic E-cadherin–N-cadherin adherens junction promotes cancer cell invasion.
2017-03-03A report in Science Translational Medicine provides the first example of using universal engineered chimeric antigen receptor (CAR) T cells from human leukocyte antigen (HLA)-mismatched donors.
2017-03-10Using data from The Cancer Genome Atlas, Carter et al. find that germline variations can influence tumour sites of origin and somatic mutations.
2017-03-23Two papers find that the histone acetylation reader function of the YEATS domain of ENL is required to sustain oncogenic transcriptional programmes for the growth and disease maintenance of acute leukaemias.
2017-02-24The past decade of cancer research has been marked by a growing appreciation of the role of immunity in cancer. Mutations in the tumour genome can cause tumours to express mutant proteins that are tumour specific and not expressed on normal cells (neoantigens). These neoantigens
2017-02-24Improvements in genomic and molecular methods are expanding the range of potential applications for circulating tumour DNA (ctDNA), both in a research setting and as a 'liquid biopsy' for cancer management. Proof-of-principle studies have demonstrated the translational potential of ctDNA for prognostication, molecular profiling and
2017-03-03How can we treat cancer more effectively? Traditionally, tumours from the same anatomical site are treated as one tumour entity. This concept has been challenged by recent breakthroughs in cancer genomics and translational research that have enabled molecular tumour profiling. The identification and validation of
2017-03-10The Opinion article from Gabriel Ichim and Stephen W. G. Tait, 'A fate worse than death: apoptosis as an oncogenic process' (Nat. Rev. Cancer16, 539–548; 2016), highlights intrinsic mechanisms of failure of commonly used cancer therapies that are heavily dependent
2017-03-10Our recent Opinion article discussed the oncogenic effects of engaging apoptosis and their impact on cancer (Nat. Rev. Cancer16, 539–548; 2016). We would like to thank Roger Chammas, Luciana Nogueira de Sousa Andrade and Sonia Jancar for their correspondence on our
2017-01-20Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and
2017-03-23Nature Reviews Cancer17, 79–92 (2017)In this article a source of grant funding for one of the authors was omitted from the Acknowledgements section. The online version of the article has been corrected to include: “The work of
2017-03-23Nature Reviews Cancer17, 160–183 (2017)Supplementary information S1–S6 (tables) for this article have been replaced, with several minor errors in the tables and references corrected.